The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial
Open accessAbstract
BACKGROUND: Accumulating evidence points toward mutual interaction between parathyroid hormone (PTH) and aldosterone as potential mechanism for increasing cardiovascular risk in primary hyperparathyroidism (pHPT). METHODS: The Eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism (EPATH) trial is a single-center, randomized, double-blind, parallel-group, placebo-controlled trial. The primary aim is to evaluate the effects of the mineralocorticoid receptor antagonist eplerenone on plasma intact PTH (iPTH) concentration in patients with pHPT. Secondary end points comprised surrogate parameters of cardiovascular health [24-h ambulatory SBP and DBP and echocardiographic parameters related to systolic/diastolic function as well as to cardiac dimensions]. RESULTS: We enrolled 110 study participants with pHPT, 25-hydroxyvitamin D at least 20 ng/ml and estimated glomerular filtration rate more than 50 ml/min per 1.73 m. Patients were 1 : 1 randomly assigned to receive either 25 mg eplerenone once daily (up-titration after 4 weeks to 50 mg/day) or matching placebo for a treatment period of 8 weeks.The study was completed by 97 participants [mean (SD) age: 67.5 ± 9.5 years; 78.4% women). The mean treatment effect (95% confidence interval) for iPTH was 1.0 (0.9-1.1; P = 0.777) pg/ml. Mean 24-h ambulatory SBP and DBP decreased significantly [mean change (95% confidence interval) -6.3 (-9.4 to -3.3) and -3.7 (-5.7 to -1.7) mmHg, respectively; P < 0.001]. No differences were seen in any further secondary outcomes or frequency of adverse events. CONCLUSION: In pHPT, treatment with eplerenone compared with placebo had no effect on circulating iPTH levels. Eplerenone treatment was well tolerated and safe and followed by significant decrease of ambulatory blood pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcium-Regulating Hormones in Essential Hypertension
Resnick, L. M., MÜLLER, F. B., & LARAGH, J. H. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-5-649 · Cited by 371
Normocalcemic Primary Hyperparathyroidism: Further Characterization of a New Clinical Phenotype
Lowe, H., McMahon, D. J., Rubin, M. R., Bilezikian, J. P., & Silverberg, S. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2802 · Cited by 353
Eastell, R., Brandi, M. L., Costa, A. G., D'AMOUR, P., Shoback, D., & Thakker, R. V. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1414 · Cited by 342
Vitamin D Status and Redefining Serum Parathyroid Hormone Reference Range in the Elderly1
Souberbielle, J., Cormier, C., Kindermans, C., Gao, P. H., Cantor, T. L., Forette, F., & Baulieu, E. E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7689 · Cited by 270
The Calcimimetic Cinacalcet Normalizes Serum Calcium in Subjects with Primary Hyperparathyroidism
Shoback, D., Bilezikian, J. P., Turner, S. A., McCary, L. C., Guo, M. D., & Peacock, M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021597 · Cited by 248
Vitamin D Status and Redefining Serum Parathyroid Hormone Reference Range in the Elderly
Souberbielle, J. C. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.7.3086 · Cited by 205
Tomaschitz, A., Ritz, E., Pieske, B. M., Rus-Machan, J., Kienreich, K., Verheyen, N., Gaksch, M., Grübler, M. R., Fahrleitner‐Pammer, A., Mrak, P., et al. (2013) · Metabolism · doi:10.1016/j.metabol.2013.08.016 · Cited by 169
Self-citationChronic continuous PTH infusion results in hypertension in normal subjects.
Hulter, H. N., Melby, J. C., Peterson, J. C., & Cooke, C. R. (1986) · PubMed · Cited by 161
Pilz, S., Tomaschitz, A., Drechsler, C., Ritz, E., Boehm, B. O., Grammer, T. B., & Marz, W. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq109 · Cited by 161
Self-citationvan Ballegooijen, A. J., Reinders, I., Visser, M., & Brouwer, I. A. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.02.014 · Cited by 143
Cited by
Sorted by citations
Cardiovascular manifestations of primary hyperparathyroidism: a narrative review
Pepe, J., Cipriani, C., Sonato, C., Raimo, O., Biamonte, F., & Minisola, S. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0485 · Cited by 165
Brandenburg, V. M., & Ketteler, M. (2022) · Nutrients · doi:10.3390/nu14153009 · Cited by 98
The Interplay Between the Renin-Angiotensin-Aldosterone System and Parathyroid Hormone
Zheng, M.-H., Li, F., Xu, F., Lin, X., Wang, Y., Xu, Q.-S., Guo, B., & Yuan, L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00539 · Cited by 69
Verdelli, C., & Corbetta, S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0430 · Cited by 58
Bislev, L. S., Rødbro, L. L., Bech, J. N., Pedersen, E. B., Kjaergaard, A. D., Ladefoged, S. A., Rolighed, L., Sikjær, T., & Rejnmark, L. (2018) · Endocrine · doi:10.1007/s12020-018-1659-4 · Cited by 28
Asbach, E., Bekeran, M., König, A., Lang, K., Hanslik, G., Treitl, M., Ladurner, R., Bidlingmaier, M., Beuschlein, F., Quinkler, M., et al. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1027-6472 · Cited by 25
Verheyen, N., Fahrleitner-Pammer, A., Pieske, B., Meinitzer, A., Belyavskiy, E., Wetzel, J., Gaksch, M., Grübler, M. R., Catena, C., Sechi, L. A., et al. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001004 · Cited by 24
Self-citationVerheyen, N., Meinitzer, A., Grübler, M. R., Ablasser, K., Kolesnik, E., Fahrleitner‐Pammer, A., Belyavskiy, E., Trummer, C., Theiler‐Schwetz, V., Pieske‐Kraigher, E., et al. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-1159 · Cited by 24
Self-citationWetzel, J., Pilz, S., Grübler, M. R., Fahrleitner‐Pammer, A., Dimai, H. P., von Lewinski, D., Kolesnik, E., Perl, S., Trummer, C., Schwetz, V., et al. (2017) · The Journal of Clinical Hypertension · doi:10.1111/jch.13064 · Cited by 22
Self-citationBislev, L. S., Rødbro, L. L., Bech, J. N., Pedersen, E. B., Rolighed, L., Sikjær, T., & Rejnmark, L. (2018) · Clinical Endocrinology · doi:10.1111/cen.13734 · Cited by 14
Verheyen, N., Fahrleitner‐Pammer, A., Belyavskiy, E., Gruebler, M. R., Dimai, H. P., Amrein, K., Ablasser, K., Martensen, J., Catena, C., Pieske‐Kraigher, E., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173799 · Cited by 14
Self-citationPilz, S., Trummer, C., Verheyen, N., Theiler‐Schwetz, V., Pandis, M., Aberer, F., Grübler, M. R., Meinitzer, A., Bachmann, A., Voelkl, J. G. J., et al. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0604-3249 · Cited by 13
Self-citationAngiotensin-Converting Enzyme Inhibition and Parathyroid Hormone Secretion
Zaheer, S., Brown, J. M., Connors, M., Williams, J. S., Adler, G. K., & Vaidya, A. (2017) · International Journal of Endocrinology · doi:10.1155/2017/4138783 · Cited by 12
Zavatta, G., Dalmazi, G. D., Altieri, P., Pelusi, C., Golfieri, R., Mosconi, C., Balacchi, C., Borghi, C., Cosentino, E. R., Cintio, I. D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.09.002 · Cited by 11
Verheyen, N., Grübler, M. R., Meinitzer, A., Trummer, C., Theiler‐Schwetz, V., Amrein, K., Dimai, H. P., März, W., Catena, C., von Lewinski, D., et al. (2017) · Bone · doi:10.1016/j.bone.2017.08.030 · Cited by 10
Self-citationSaline suppression testing-induced hypocalcemia and implications for clinical interpretations
Parksook, W. W., Brown, J. M., Milks, J., Tsai, L. C., Chan, J., Moore, A., Niebuhr, Y., Honzel, B., Newman, A. J., & Vaidya, A. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae099 · Cited by 6
Gueiros, A. P. S., Gueiros, J. E. B., Nóbrega, K. T., Calado, E. B., da Matta, M. C., Torres, L. C., Souza, A. S. R., Casarini, D. E., & Carvalho, A. B. (2019) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2019-0009 · Cited by 6
Hyperparathyroidism in patients with overt and mild primary aldosteronism
Gravvanis, C., Papanastasiou, L., Glycofridi, S., Voulgaris, N., Tyfoxylou, E., Kounadi, T., Piaditis, G. P., & Markou, Α. (2021) · HORMONES · doi:10.1007/s42000-021-00319-w · Cited by 5
Dobreva, E. A., Евгеньевна, Б. Е., Константиновна, Е. А., Rebrova, O. Y., Nikankina, L. V., Malysheva, N. M., & Mokrysheva, N. G. (2020) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2019-25-6-630-638 · Cited by 5
Dobreva, E. A., Bibik, E. E., Eremkina, A. K., Ajnetdinova, A. R., Nikankina, L. V., Malysheva, N. M., & Mokrysheva, N. G. (2020) · Terapevticheskii Arkhiv · doi:10.26442/00403660.2020.10.000725 · Cited by 4
“В когорте пациентов с ПГПТ получены противоречивые результаты в отношении изменения концентрации параметров РААС, а также уровня ПТГ при приеме препаратов, влияющих на активность данной системы регуляции АД [22, 23].”
Systematic approach to the diagnosis and management of endocrine hypertension
Stowasser, M., Jansen, P. M., & Wolley, M. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-96120-2.00009-1 · Cited by 4
Corticosteroid rhythms in hypoparathyroid patients
Astor, M. C., Løvås, K., Methlie, P., Šimůnková, K., Aßmus, J., & Husebye, E. S. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae102 · Cited by 2
Double hit! A unique case of resistant hypertension
DeCarlo, K., & Agrawal, N. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-221530 · Cited by 2
Parksook, W. W., Heydarpour, M., Brown, J. M., Turchin, A., Mannstadt, M., & Vaidya, A. (2022) · Clinical Endocrinology · doi:10.1111/cen.14840 · Cited by 1
Metadata
- Authors
- Tomaschitz, A., Verheyen, N., Meinitzer, A., Pieske, B., Belyavskiy, E., Brussee, H., Haas, J., März, W., Pieske-Kraigher, E., Verheyen, S., Ofner-Ziegenfuss, L., Hartaigh, B. Ó., Schwetz, V., Aberer, F., Grübler, M., Lang, F., Alesutan, I., Voelkl, J., Gaksch, M., Horina, J. H., Dimai, H.-P., Rus-Machan, J., Stiegler, C., Ritz, E., Fahrleitner-Pammer, A., & Pilz, S.
- Affiliations
- University of Mannheim (DE)
- Medical University of Graz (AT)
- Corresponding author
- Pilz, Stefan
- ORCID
- Venue
- Journal of Hypertension
- Published
- 2016-07
- Volume
- 34
- Issue
- 7
- Pages
- 1347-1356
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W2338117764
- Cited by
- 24
- References
- 43
- Citations by year
- 2024: 2 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 7 · 2016: 2
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- other-oa
- Locations
- Journal of Hypertension (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Pfizer
- Oesterreichische Nationalbank (14621, 13905, 13878)
- Karl-Franzens-Universität Graz
- Medizinische Universität Graz
- Topics
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- eplerenone, primary hyperparathyroidism, parathyroid hormone, mineralocorticoid receptor antagonists, aldosterone, cardiovascular risk, ambulatory blood pressure, systolic and diastolic function, echocardiography
- MeSH terms
- Eplerenone, Aged, Mineralocorticoid Receptor Antagonists, Blood Pressure, Diastole, Double-Blind Method, Echocardiography, Female, Humans, Hypertension, Male, Middle Aged, Parathyroid Hormone, Spironolactone, Systole, Vitamin D, Blood Pressure Monitoring, Ambulatory, Hyperparathyroidism, Primary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
